Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

Nopsopon, Tanawin; Kittrakulrat, Jathurong; Takkavatakarn, Kullaya; Eiamsitrakoon, Thanee; Kanjanabuch, Talerngsak; Pongpirul, Krit

doi:10.1371/journal.pntd.0009156

Cited by 22 publications

(22 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This possibility is supported by the policy of some hospitals such as the university hospital of Geneva (HUG), where many patients who died from COVID-19 would not have been admitted to an ICU because of local triage criteria ( 6 ). Our findings, again, are supported by the above mentioned review and meta-analysis ( 12 ), which showed that ESRD patients have a 3.6 times higher risk of dying than the general population in the first wave.…”

Section: Discussionsupporting

confidence: 89%

“…Third, contact with health care workers is also a potential source of transmission, what is supported by the fact that patients on 1–2 dialysis sessions per week or on PD were tested less often positive for SARS-CoV-2 than patients on thrice-weekly dialysis schedules ( Table 6 ). A systematic review and meta-analysis from the first wave from Nopsopon et al ( 12 ) supports our findings with end-stage renal disease (ESRD) patients getting tested positive much more often than the general population.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

COVID-19 Pandemic in Dialysis Patients: The Swiss Experience

Guidotti

Pruijm

Ambühl

2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundChronic dialysis patients are classified as patients with increased risk for COVID-19. Knowledge about the incidence and survival of chronic dialysis patients infected with SARS-CoV-2 in Switzerland - a high-income country with high density of relatively small dialysis centers - is scarce. We present the findings regarding incidence, survival and regional differences, compared to those of the general population in Switzerland.MethodsInformation on chronic dialysis patients who tested positive for SARS-CoV-2 between February 24, 2020 and February 28, 2022 were reported to the Swiss dialysis registry by all 94 Swiss dialysis centers. Hereafter, these results were linked with clinical characteristics from the Swiss dialysis registry.ResultsThroughout the study period 1,120 out of ~4,700 dialysis patients tested positive for SARS-CoV-2 in Switzerland: 96 cases occurred in the first wave, 472 in the second wave and 5 in between. During the first wave, Italian-speaking Ticino was most severely affected, with a 7-fold higher incidence of dialysis patients compared to the general Swiss population. In the second wave, the majority of cases were found in the French-speaking part of Switzerland, with a 2.5 times higher incidence vs. non-dialysis patients. A total of 123 deaths were recorded in the first two waves, of which COVID-19 was the main cause of death in 100 patients. This corresponds to a highly increased overall mortality rate of 17.5% compared to 1.7% in the general population. Age was identified as the only risk factor for mortality in dialysis patients. During the third, fourth and fifth wave, 61, 43 and 443 cases, respectively, were recorded, resulting in 6 (mortality rate 9.8%), 1 (mortality rate 2.3%) and 13 deaths (mortality rate 2.9%).ConclusionChronic dialysis patients in Switzerland were more likely to be infected by SARS-CoV-2 during the first and second wave than the rest of the population, but an inverse trend was observed during the third, fourth and fifth wave, probably thanks to vaccination. In addition, mortality is significantly increased compared to non-dialysis patients. In Swiss dialysis patients, age is the strongest risk factor for death.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 83%

COVID-19 Pandemic in Dialysis Patients: The Swiss Experience

Guidotti

Pruijm

Ambühl

2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic has been particularly challenging for vulnerable patients receiving HD. A meta-analysis (15 studies, 20,671 participants) reported that the prevalence of COVID-19 among patients on KRT was 3.1% (95% CI 1.3%–5.7%) and the mortality rate was 18.1% (95% CI 14.1–23.3) 99 . Of note, these prevalence and mortality rates vary according to community transmission rates at the time.…”

Section: Clinical Hd Outcomes Across the Globementioning

confidence: 99%

Epidemiology of haemodialysis outcomes

et al. 2022

View full text Add to dashboard Cite

Haemodialysis (HD) is the commonest form of kidney replacement therapy in the world, accounting for approximately 69% of all kidney replacement therapy and 89% of all dialysis. Over the last six decades since the inception of HD, dialysis technology and patient access to the therapy have advanced considerably, particularly in high-income countries. However, HD availability, accessibility, cost and outcomes vary widely across the world and, overall, the rates of impaired quality of life, morbidity and mortality are high. Cardiovascular disease affects more than two-thirds of people receiving HD, is the major cause of morbidity and accounts for almost 50% of mortality. In addition, patients on HD have high symptom loads and are often under considerable financial strain. Despite the many advances in HD technology and delivery systems that have been achieved since the treatment was first developed, poor outcomes among patients receiving HD remain a major public health concern. Understanding the epidemiology of HD outcomes, why they might vary across different populations and how they might be improved is therefore crucial, although this goal is hampered by the considerable heterogeneity in the monitoring and reporting of these outcomes across settings.

show abstract

“…When compared to general population, COVID‐19 has high mortality in end‐stage renal disease (ESRD) 1 patients. Prevention of virus spread among ESRD patients is of paramount importance.…”

Section: Introductionmentioning

confidence: 99%

Antibody responses to inactivated SARS‐CoV‐2 vaccine in peritoneal dialysis patients

Murt

Altiparmak

Özbey

et al. 2022

Seminars in Dialysis

View full text Add to dashboard Cite

Introduction As end‐stage renal disease (ESRD) patients generally have reduced responses to the vaccines, effectiveness of newly developed SARS‐CoV‐2 vaccines in ESRD are also matters of curiosity. We aimed to investigate the humoral responses of our peritoneal dialysis (PD) patients to the inactivated SARS‐CoV‐2 vaccine. Methods Humoral immune responses of 23 PD patients who received two doses of the inactivated SARS‐CoV‐2 vaccine were investigated with a commercial test that measures IgG antibodies towards receptor binding domain of SARS‐CoV‐2 spike protein. Seropositivity rates, antibody titers, and ESRD related clinical data were compared with 51 hemodialysis (HD) patients and 29 healthy volunteers. Results Seropositivity of PD patients with the inactivated vaccine was 95.6%. Both the rate of seropositivity and SARS‐CoV‐2 IgG antibody levels in PD patients were not different from the healthy controls (p = 0.85 and 0.19, respectively). While seropositivity rates were not different for PD or HD patients (p = 0.09), the magnitude of humoral responses was significantly higher in PD patients (p = 0.0001). There were no vaccine‐related serious adverse events. In the 3‐months clinical follow‐up, none of the patients experienced SARS‐CoV‐2 infection. Conclusion Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.

show abstract

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

Cited by 22 publications

References 64 publications

COVID-19 Pandemic in Dialysis Patients: The Swiss Experience

COVID-19 Pandemic in Dialysis Patients: The Swiss Experience

Epidemiology of haemodialysis outcomes

Antibody responses to inactivated SARS‐CoV‐2 vaccine in peritoneal dialysis patients

Contact Info

Product

Resources

About